ACM
NBIX icon

Americafirst Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Americafirst Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-46,841
Closed -$734M – 266
2014
Q3 		$734M Buy
+46,841
New +$700K 0.36% 98

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Americafirst Capital Management's NBIX Position: Q4 2014 in Review

Americafirst Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2014, closing a stake of 46,841 shares — an estimated $734M sold.

Americafirst Capital Management first reported a position in NBIX in Q3 2014 and held it in 1 quarter. The position peaked at $734M in Q3 2014. 133 funds tracked by Wall St. Rank hold NBIX as of Q4 2014.

  • Americafirst Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2014 after selling out during the quarter.
  • Americafirst Capital Management sold 46,841 Neurocrine Biosciences shares in Q4 2014, an estimated $734M.
  • Americafirst Capital Management first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 1 quarter.
  • Americafirst Capital Management's Neurocrine Biosciences position peaked at $734M in Q3 2014.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2014.

Based on Americafirst Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.